Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 Aspergillus Section Nigri Isolates

Aspergillus niger, the third species responsible for invasive aspergillosis, has been considered as a homogeneous species until DNA-based identification uncovered many cryptic species. These species have been recently reclassified into the Aspergillus section Nigri. However, little is yet known among the section Nigri about the species distribution and the antifungal susceptibility pattern of each cryptic species. A total of 112 clinical isolates collected from 5 teaching hospitals in France and phenotypically identified as A. niger were analyzed. ABSTRACT Aspergillus niger, the third species responsible for invasive aspergillosis, has been considered as a homogeneous species until DNA-based identification uncovered many cryptic species. These species have been recently reclassified into the Aspergillus section Nigri. However, little is yet known among the section Nigri about the species distribution and the antifungal susceptibility pattern of each cryptic species. A total of 112 clinical isolates collected from 5 teaching hospitals in France and phenotypically identified as A. niger were analyzed. Identification to the species level was carried out by nucleotide sequence analysis. The MICs of itraconazole, voriconazole, posaconazole, isavuconazole, and amphotericin B were determined by both the EUCAST and gradient concentration strip methods. Aspergillus tubingensis (n = 51, 45.5%) and Aspergillus welwitschiae (n = 50, 44.6%) were the most common species while A. niger accounted for only 6.3% (n = 7). The MICs of azole drugs were higher for A. tubingensis than for A. welwitschiae. The MIC of amphotericin B was 2 mg/liter or less for all isolates. Importantly, MICs determined by EUCAST showed no correlation with those determined by the gradient concentration strip method, with the latter being lower than the former (Spearman’s rank correlation tests ranging from 0.01 to 0.25 depending on the antifungal agent; P > 0.4). In conclusion, A. niger should be considered as a minority species in the section Nigri. The differences in MICs between species for different azoles underline the importance of accurate identification. Significant divergences in the determination of MIC between EUCAST and the gradient concentration strip methods require further investigation.

[1]  T. Toyotome,et al.  Prospective survey of Aspergillus species isolated from clinical specimens and their antifungal susceptibility: A five-year single-center study in Japan. , 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  R. Piarroux,et al.  Multi-centric evaluation of the online MSI platform for the identification of cryptic and rare species of Aspergillus by MALDI-TOF. , 2019, Medical mycology.

[3]  L. Trovato,et al.  Environmental Isolates of Multi-Azole-Resistant Aspergillus spp. in Southern Italy , 2018, Journal of fungi.

[4]  C. Deluca,et al.  Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods , 2018, Antimicrobial Agents and Chemotherapy.

[5]  Hsuan‐Chen Wang,et al.  Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species , 2018, Journal of Clinical Microbiology.

[6]  M. Faria,et al.  Aspergillus Species and Antifungals Susceptibility in Clinical Setting in the North of Portugal: Cryptic Species and Emerging Azoles Resistance in A. fumigatus , 2018, Front. Microbiol..

[7]  Y. Le Govic,et al.  Successful treatment of a recurrent Aspergillus niger otomycosis with local application of voriconazole. , 2018, Journal de mycologie medicale.

[8]  R. Arenas,et al.  Identification of Aspergillus tubingensis in a primary skin infection. , 2018, Journal de mycologie medicale.

[9]  S. Rezaie,et al.  Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients. , 2018, Journal de mycologie medicale.

[10]  R. Herbrecht,et al.  Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity. , 2018, Journal de mycologie medicale.

[11]  R. Piarroux,et al.  Black aspergilli: A remaining challenge in fungal taxonomy? , 2017, Medical mycology.

[12]  J. Frisvad,et al.  Aspergillus labruscus sp. nov., a new species of Aspergillus section Nigri discovered in Brazil , 2017, Scientific Reports.

[13]  D. Hagiwara,et al.  Drug Sensitivity and Resistance Mechanism in Aspergillus Section Nigri Strains from Japan , 2017, Antimicrobial Agents and Chemotherapy.

[14]  J. Turnidge,et al.  Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method , 2016, Antimicrobial Agents and Chemotherapy.

[15]  G. Goldman,et al.  Epidemiological and Genomic Landscape of Azole Resistance Mechanisms in Aspergillus Fungi , 2016, Front. Microbiol..

[16]  G. Crescenzo,et al.  Species Distribution and In Vitro Azole Susceptibility of Aspergillus Section Nigri Isolates from Clinical and Environmental Settings , 2016, Journal of Clinical Microbiology.

[17]  S. Ranque,et al.  Aspergillus tubingensis: a major filamentous fungus found in the airways of patients with lung disease. , 2016, Medical mycology.

[18]  B. Alexander,et al.  Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds , 2015, Journal of Clinical Microbiology.

[19]  Wei Liu,et al.  Identification and Susceptibility of Aspergillus Section Nigri in China: Prevalence of Species and Paradoxical Growth in Response to Echinocandins , 2014, Journal of Clinical Microbiology.

[20]  L. Dupont,et al.  Invasive Aspergillus niger complex infections in a Belgian tertiary care hospital. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  M. Arendrup,et al.  EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  D. Denning,et al.  Cryptic Species and Azole Resistance in the Aspergillus niger Complex , 2011, Antimicrobial Agents and Chemotherapy.

[23]  E. Mellado,et al.  Species Identification and Antifungal Susceptibility Patterns of Species Belonging to Aspergillus Section Nigri , 2009, Antimicrobial Agents and Chemotherapy.

[24]  J. Meis,et al.  Effect of pH on the In Vitro Activities of Amphotericin B, Itraconazole, and Flucytosine against Aspergillus Isolates , 2004, Antimicrobial Agents and Chemotherapy.